Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generation of human iPSCs from an essential thrombocythemia patient carrying a V501L mutation in the MPL gene.

Stem cell research - 1 Jan 2017

Liu Senquan, Ye Zhaohui, Gao Yongxing, He Chaoxia, Williams Donna W, Moliterno Alison, Spivak Jerry, Huang He, Cheng Linzhao

Abstract excerpt

Activating point mutations in the MPL gene encoding the thrombopoietin receptor are found in 3%-10% of essential thrombocythemia (ET) and myelofibrosis patients. Here, we report the derivation of induced pluripotent stem cells (iPSCs) from an ET patient with a heterozygous MPL V501L mutation. Peripheral blood CD34+ progenitor cells were reprogrammed by transient plasmid expression of OCT4, SOX2, KLF4, c-MYC plus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to Cellular Reprogramming

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Embryoid Bodies

Share to Karyotype

Share to Kruppel-Like Factor 4

Share to Receptors, Thrombopoietin

Share to Teratoma

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 28395806
DOI: 10.1016/j.scr.2016.12.012

Genes

MPL
KLF4
MYC
SOX2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generation of human iPSCs from an essential thrombocythemia patient carrying a V501L mutation in the MPL gene.PMID 28395806Read ↗

Application of iPS cells derived from congenital myelodysplastic syndrome for research of nomal hematopoesis and hematological malignancies.Semantic proximity Read ↗

Generation of a human iPSC line (MPIi006-A) from a patient with Pelizaeus-Merzbacher disease.Semantic proximity Read ↗

Generation of an induced pluripotent stem cell line from a patient with Loeys-Dietz syndrome.Semantic proximity Read ↗

Generation of induced pluripotent stem cells from peripheral blood CD34 + hematopoietic progenitors of a 31 year old healthy womanSemantic proximity Read ↗

Generation of a human iPSC line (MPIi007-A) from a patient with Metachromatic leukodystrophy.Semantic proximity Read ↗

Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.Semantic proximity Read ↗

Generation of the human induced pluripotent stem cell line (ZJUi005-A) from a patient with Pelizaeus-Merzbacher disease (PMD) carrying a novel hemizygous mutation in PLP1 gene.Semantic proximity Read ↗

Generation of three lines from multiorgan venous and lymphatic defect syndrome patients.Semantic proximity Read ↗

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.Semantic proximity Read ↗

Generation of four iPSC lines from four patients with Leigh syndrome carrying homoplasmic mutations m.8993T > G or m.8993T > C in the mitochondrial gene MT-ATP6.Semantic proximity Read ↗

In silico analysis of Missense Variants in Human MPL Gene Associated with Essential ThrombocythemiaSemantic proximity Read ↗

Establishment of isogenic induced pluripotent stem cells with or without pathogenic mutation for understanding the pathogenesis of myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.